Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development.

Arash Keshavarzi Arshadi¹, Julia Webb¹, Milad Salem², Emmanuel Cruz³, Stacie Calad-Thomson⁴, Niloofar Ghadirian⁵, Jennifer Collins¹, Elena Diez-Cecilia³, Brendan Kelly³, Hani Goodarzi⁶, Jiann Shiun Yuan²

¹Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, United States.

²Department of Electrical and Computer Engineering, University of Central Florida, Orlando, FL, United States.

³A2A Pharmaceuticals, Cambridge, MA, United States.

⁴Atomwise Inc., San Francisco, CA, United States.

⁵Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, United States.

⁶Department of Biochemistry and Biophysics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States.

PubMed PMC DOI PDF

Abstract

SARS-COV-2 has roused the scientific community with a call to action to combat the growing pandemic. At the time of this writing, there are as yet no novel antiviral agents or approved vaccines available for deployment as a frontline defense. Understanding the pathobiology of COVID-19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. One method…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.